Kymera Therapeutics, Inc.

KYMRNasdaq· Biological Products, (No Diagnostic Substances)

Price History

Revenue

$39.2M

▼ 16.7% YoY

Net Income

-$311.4M

▼ 39.1% YoY

EPS

$-3.69

▼ 23.8% YoY

Cash

$357.0M

▲ 196.9% YoY

FY 2025 · As of 2025-12-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.